NEW YORK — August 25, 2025 — Leads & Copy — Bright Minds Biosciences Inc. (NASDAQ: DRUG) will present at several upcoming conferences, including the 36th International Epilepsy Congress in Lisbon, Portugal, from August 30 to September 3, 2025. The company will also present at the Cantor Global Healthcare Conference 2025 on September 5, 2025, at 9:45 am ET, with a live webcast available. Additionally, Bright Minds will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:00 pm ET and the Baird 2025 Global Healthcare Conference on September 10, 2025, at 9:05 am ET.
Bright Minds Biosciences is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other central nervous system disorders. The live and archived webcast for the Cantor event will be accessible from the Company’s website under Events and Presentation. The replay of the webcast will be accessible for 60 days.
Bright Minds Biosciences develops innovative treatments for patients with neurological and psychiatric disorders, including novel compounds targeting key receptors in the brain to address conditions with high unmet medical need. The company has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors, providing a portfolio of NCE programs within neurology and psychiatry.
Contact Information:
Investor Relations: Lisa M. Wilson, T: 212-452-2793, E: lwilson@insitecony.com; Alex Vasilkevich, Chief Operating Officer, Bright Minds Biosciences Inc., T: 414-731-6422, E: alex@brightmindsbio.com
Source: Bright Minds Biosciences
